1999
DOI: 10.1038/sj.bmt.1701903
|View full text |Cite
|
Sign up to set email alerts
|

Donor lymphocyte infusion post-non-myeloablative allogeneic peripheral blood stem cell transplantation for chronic granulomatous disease

Abstract: Summary:Chronic granulomatous disease (CGD) is a primary immunodeficiency disease symptomized by failure to generate superoxide and recurrent bacterial and fungal infections. Allogeneic bone marrow transplantation (BMT) is one of the therapeutic options available. However, it presents considerable risk to the recipient, especially if the patient is already at an advanced stage of disease, after repeated bacterial and fungal infections and organ damage. We present a case report of a 6-year-old child with long-s… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
20
0
1

Year Published

2000
2000
2010
2010

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 47 publications
(22 citation statements)
references
References 18 publications
1
20
0
1
Order By: Relevance
“…Overall, 7 patients have survived from 16 to 26 months, there were 2 deaths related to the procedure from pneumococcal pneumonia and GVHD, respectively, anda third patient who rejected the gran died anera second transplant. A similar approach was reported by Nagler that resulted in full chimerism with no GVHD in a child with CGD [27].…”
Section: Nonmyeloablative Hematopoietic Cell Transplants For Treatmensupporting
confidence: 59%
“…Overall, 7 patients have survived from 16 to 26 months, there were 2 deaths related to the procedure from pneumococcal pneumonia and GVHD, respectively, anda third patient who rejected the gran died anera second transplant. A similar approach was reported by Nagler that resulted in full chimerism with no GVHD in a child with CGD [27].…”
Section: Nonmyeloablative Hematopoietic Cell Transplants For Treatmensupporting
confidence: 59%
“…The 4 deaths occurred only in the group of patients with pre-existing fungal infections refractory to all conventional treatments. We can therefore conclude that HLA-genoidentical HSCT, hitherto reported only in individual CGD patients, [6][7][8][9][10][11][17][18][19][20][21][22] is a valid alternative to conventional treatment.…”
Section: Discussionmentioning
confidence: 99%
“…Other investigators have reported stem cell boosts, 28 DLI, 29 or CD34 þ -enriched DLI 30 as an effective therapy for declining donor chimerism, poor graft function, or mixed chimerism. Anti-T cell therapy with ATG and CAMPATH proved ineffective at stabilizing mixed chimerism in patient 2.…”
Section: Discussionmentioning
confidence: 99%